Here are four things to know.
1. Kaléo already covers out-of-pocket costs for commercially insured patients with a prescription for the naloxone auto-injector.
2. The company will now offer Evzio at no cost to commercially insured patients without a prescription via a pilot program in six states: Arizona, California, Colorado, Missouri, Nevada and Ohio. Kaléo will eventually expand the program to additional states.
3. The company will also allow all federal and state government agencies to directly purchase Evzio at a discounted price of $360 for a two-pack of auto-injectors.
4. The initiatives come a year after Kaléo faced congressional scrutiny over Evzio’s high price, which jumped from $690 in 2014 to $4,500 in 2017. The list price is now $4,100 for a two-pack, according to Reuters.
More articles on supply chain:
Study: 40% of providers have canceled surgeries over supply shortages
10 immensely overinflated hospital costs
Beating Amazon to the punch: Zipline launches drone to deliver medical supplies at 79 mph
.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
